In conclusion, the use of CD4-IL15/IL15sushi CAR T cells led to remission (2 CR, 1 PR) in three patients with PTCL/CTCL without serious adverse effects in a phase I clinical trial. This evidence concerns the gene CD4 and primary cutaneous T-cell non-Hodgkin lymphoma.